Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Neoplasm Metastasis 2Colorectal Neoplasms 2Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Neuroblastoma 1Gastrointestinal Neoplasms 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Advanced Esophageal Squamous Cell Cancer 1

Interventions

irinotecan sucrosofate 1Taxes 1Radiosurgery 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Cancer Non-resectable × irinotecan sucrosofate × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡